NTLA — Intellia Therapeutics, Inc.

Summary of Intellia Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Intellia had $669.9 million in cash, cash equivalents, and marketable securities, down from $861.7 million at the end of 2024.
• Funding: Raised approximately $115 million through an At-the-Market (ATM) facility during the quarter.
• Collaboration Revenue: Increased to $13.8 million from $9.1 million year-over-year, primarily due to cost reimbursements from Regeneron Pharmaceuticals.
• R&D Expenses: Decreased to $94.7 million from $123.4 million year-over-year, attributed to reduced employee-related expenses and stock-based compensation.
• Net Loss: Reported at $101.3 million, down from $135.7 million in the prior year quarter.
• Operating Expenses Guidance: Expected a year-over-year decline of at least 10% in GAAP operating expenses.

2. Strategic Updates and Business Highlights

• Nex-z Program: Progress in the Phase III MAGNITUDE trials for ATTR amyloidosis has been halted due to a clinical hold from the FDA following a serious adverse event involving a patient who passed away. Safety monitoring protocols are being enhanced.
• Lonvo-z Program: The Phase III HAELO trial for hereditary angioedema (HAE) completed enrollment in September 2025, with top-line data expected by mid-2026 and a BLA submission anticipated in the second half of 2026.

3. Forward Guidance and Outlook

• Nex-z: Unable to provide milestone guidance due to the clinical hold. Updates will follow once a plan with regulators is finalized.
• Lonvo-z: The company remains on track for a potential commercial launch in the U.S. in the first half of 2027.

4. Bad News, Challenges, or Points of Concern

• Clinical Hold: The FDA has placed a clinical hold on both MAGNITUDE and MAGNITUDE-2 trials due to safety concerns, significantly impacting the nex-z program.
• Patient Safety Incident: A patient in the MAGNITUDE trial experienced severe liver enzyme elevations and subsequently passed away, raising concerns about the safety profile of nex-z.
• Regulatory Uncertainty: The company is awaiting formal communication from the FDA regarding the clinical hold, which adds uncertainty to timelines and operational plans.

5. Notable Q&A Insights

• Safety Concerns: Management refrained from speculating on the cause of liver enzyme elevations but acknowledged ongoing investigations into patient data to identify risk factors.
• Financial Management During Hold: CFO Ed Dulac indicated that while patient enrollment is paused, operational costs may decrease slightly due to the lack of new patient dosing.
• Risk Mitigation Strategies: The company is exploring additional monitoring and risk mitigation strategies for both nex-z and lonvo-z programs.
• Commercial Impact: While there are concerns about the potential impact of the adverse event on the commercial opportunity for lonvo-z, management remains optimistic based on the data they will present at upcoming conferences.

Overall, Intellia is navigating significant challenges with its nex-z program while maintaining progress with lonvo-z, though the clinical hold presents a critical hurdle that could affect future operations and timelines.